To further explore the issue, we stratified patients with NPM1-mutated AML as unfavorable risk, along with FLT3-ITD, based on presence of these MDS-associated gene mutations and TP53 mutations using NGS profiling. This evidence concerns the gene NPM1 and acute myeloid leukemia.